a life science company dedicated to providing state-of-the-art chemical and biotechnology
products to the world''s researchers and listed on Nasdaq, along with leading gene
therapy company, the London Stock Exchange-listed Oxford BioMedica, have announced
that they have received a key order confirming the strength and validity of intellectual
property owned by Oxford BioMedica and licensed exclusively in the research field
ruling was part of the construction of patent claim terms in the patent infringement
suit brought against Open Biosystems, Inc by Oxford BioMedica. The suit, pending
in the US District Court for the Eastern District of Missouri, alleges that Open
Biosystems infringes Oxford BioMedica''s US Patents (Nos. 6,924,123 and 7,056,699)
entitled Lentiviral LTR Deleted Vector, which are owned by Oxford BioMedica and
exclusively licensed to Sigma-Aldrich for research use, by selling, among other
products, Open Biosystems'' Lentiviral shRNAmir Library.
his order US District Judge Charles A. Shaw concluded "that the constructions
of the disputed terms and phrases proposed by plaintiff are correct."
are gratified and very pleased that the court has adopted Sigma''s and Oxford''s
definitions of all disputed claim terms in this case," said David Smoller,
president, Research Biotechnology Business Unit of Sigma-Aldrich.
added, "This order reinforces Sigma''s belief that the Oxford Biomedica patents
are "core patents" in the RNA-interference field, and validates Sigma''s
decision to license these patents and make other significant investments in creating
a comprehensive portfolio of intellectual property that allows our customers to
use this extraordinary technology without fear of interference or unfair competition.
We will continue to vigorously defend Oxford''s extraordinary inventions and Sigma''s
investment in this valuable intellectual property."
Nolan, SVP commercial development at Oxford BioMedica, said, "I am delighted
with this order, which validates Oxford BioMedica''s patents and strengthens our
position in this field."
BioMedica''s LentiVector system has broad applications in gene delivery and can
be used to deliver shRNA-encoding DNA to cells to enable RNA Interference (RNAi)
experiments. Based on discoveries by Oxford Biomedica''s Drs Susan and Alan Kingsman
and others, scientists are now able to safely use modified lentiviruses as vectors,
which enable RNAi to be effectively utilized as a research tool to unlock the
secrets of the genetic code. As stated in the court''s order, the viral vector
developed by the Kingsmans'' is expected to be useful as a "smart bomb"
to safely "deliver new genetic material into specific cells, such as cells
that do not divide or that divide slowly," giving the delivery of genes that
produce dopamine into a Parkinson''s disease patient''s brain cells, as an example.
believes this technology holds huge promise to better understand the human genome
and to, ultimately, help devise techniques to defeat and diminish longstanding
misery-causing diseases such as Parkinson''s and Alzheimer''s," said Smoller.
is a leading Life Science and high technology company. Its biochemical and organic
chemical products and kits are used in scientific and genomic research, biotechnology,
pharmaceutical development, the diagnosis of disease and as key components in
pharmaceutical and other high technology manufacturing. The company''s customers
span life science companies, university and government institutions, hospitals,
and industry, while over one million scientists and technologists use its products.
Sigma-Aldrich operates in 36 countries and has 7,800 employees providing excellent
company Oxford BioMedica specialises in the development of novel gene-based therapeutics
with a focus on oncology and neurotherapy. The company was established in 1995
as a spin out from Oxford University. Oxford BioMedica has core expertise in gene
delivery, as well as in-house clinical, regulatory and manufacturing know-how.
is underpinned by over 80 patent families, which represent one of the broadest
patent estates in the field. Its staff of approximately 80 are split between its
main facilities in Oxford and its wholly owned subsidiary, the San Diego-based
BioMedica Inc, in California, USA.
corporate partners include Sanofi-Aventis for TroVax and Wyeth for the targeted
antibody therapy. The Company also has corporate collaborations with MolMed and
Virsys. Technology licensees include Biogen Idec, Merck & Co., GlaxoSmithKline